The dosage of the serine threonine kinase DYRK1A is critical in the central nervous system (CNS) during development and aging. This review analyzes the functions of this kinase by considering its interacting partners and pathways. The role of DYRK1A in controlling the differentiation of prenatal newly formed neurons is presented separately from its role at the pre- and post-synaptic levels in the adult CNS; its effects on synaptic plasticity are also discussed. Because this kinase is positioned at the crossroads of many important processes, genetic dosage errors in this protein produce devastating effects arising from DYRK1A deficiency, such as in MRD7, an autism spectrum disorder, or from DYRK1A excess, such as in Down syndrome. Effects of these errors have been shown in various animal models including Drosophila, zebrafish, and mice. Dysregulation of DYRK1A levels also occurs in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Finally, this review describes inhibitors that have been assessed in vivo. Accurate targeting of DYRK1A levels in the brain, with either inhibitors or activators, is a future research challenge.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharmthera.2018.09.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prioritizing Parkinson's disease risk genes in genome-wide association loci.
medRxiv
December 2024
Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Recent advancements in Parkinson's disease (PD) drug development have been significantly driven by genetic research. Importantly, drugs supported by genetic evidence are more likely to be approved. While genome-wide association studies (GWAS) are a powerful tool to nominate genomic regions associated with certain traits or diseases, pinpointing the causal biologically relevant gene is often challenging.
View Article and Find Full Text PDFPlasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's disease.
medRxiv
November 2024
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Article Synopsis
- * A new plasma test measuring p-tau212 levels shows high accuracy in detecting AD-related changes and was tested in 245 plasma and 114 cerebrospinal fluid samples using advanced technology.
- * Results indicate a strong correlation between plasma and CSF p-tau212 levels, with elevated levels in individuals with prodromal and dementia stages of DS, demonstrating high diagnostic accuracy in distinguishing between asymptomatic and symptomatic cases.
Development and Evaluation of ABI-171, a New Fluoro-Catechin Derivative, for the Treatment of Idiopathic Pulmonary Fibrosis.
Int J Mol Sci
November 2024
Center for Interstitial Lung Diseases, University of Washington Medical Center, Seattle, WA 98195, USA.
Article Synopsis
- Researchers developed a new small molecule, ABI-171, targeting specific kinases related to idiopathic pulmonary fibrosis (IPF) to combat its progression and high mortality rates.
- In a mouse model, ABI-171 showed significant improvements in lung health, reducing fibrosis and inflammation, as well as weight loss in treated mice, whether given before or after disease onset.
- The treatment led to lower mortality rates and better overall lung function compared to current treatments like pirfenidone and EGCG, indicating ABI-171's potential as a promising therapy for IPF.
Identification, biological evaluation, and crystallographic analysis of coumestrol as a novel dual-specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor.
Int J Biol Macromol
December 2024
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address:
Alzheimer's disease (AD) is an irreversible neurodegenerative disease, with tau pathology caused by abnormally activated dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) being one of the culprits. Coumestrol, a phytoestrogen and natural antioxidant found in various plants, has been reported to alleviate AD, but the underlying mechanism remains unclear. We confirmed coumestrol as a novel DYRK1A inhibitor through enzyme-based assays, X-ray crystallography, and cell line experiments.
View Article and Find Full Text PDFErlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD.
Front Immunol
October 2024
Department of Neural Development and Disease, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea.
Article Synopsis
- Erlotinib, an EGFR inhibitor approved for lung cancer, may also impact Alzheimer's disease by targeting amyloid β interactions.
- In experiments with mouse models for AD, erlotinib treatment improved cognitive function, reduced tau phosphorylation and aggregation, and decreased astrogliosis.
- Overall, erlotinib showed potential as a therapeutic agent for Alzheimer's by enhancing memory and reducing pathological features in the brain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!